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ABSTRACT 
Leishmaniasis is an endemic disease in tropical and subtropical regions of the world, 
where it is mainly manifested within mammals.  This zoonotic disease is caused by an 
infection with a protozoan parasite called Leishmania, which resides within the mammal’s 
macrophages and/or dendritic cells.   
In this study we worked with 2 different species of Leishmania responsible for the 
cutaneous form of the disease, Leishmania major and Leishmania amazonensis.  Generally, 
when C3H mice are infected with L. major, the mice display cutaneous self-healing lesions.  
The resolution of these lesions is characterized by a strong Th1 response.  However, when 
C3H mice are infected with L. amazonensis, lesions do not heal due to an inability of the 
mice to mount an effective Th1 response. 
This study was aimed to determine the effects of L. major and L. amazonensis on 
dendritic cells migration in vitro.  Bone marrow derived-dendritic cells were infected with 
both the promastigotes and the amastigotes forms of L. major and L. amazonensis to detect 
differences between species or morphological forms.  These studies indicate that bone 
marrow derived-dendritic cells infected with L. amazonensis amastigote after 24 hour display 
an impaired migration towards MIP-3ß and produce much lower levels of IL-12p40, an 
important Th1 cytokine, than cells infected with L. major amastigotes.  These two major 
events may very well play an important role on susceptibility to L. amazonensis infection. 
1 
  
1. INTRODUCTION 
Leishmania 
The Leishmania parasite is classified as a protozoan belonging to the order 
Kinetoplastida. (1) It is transmitted to the host by an infected female sandfly.  Leishmania is 
considered a mammalian parasite, although there are species of Leishmania known to infect 
other vertebrates, i.e. reptiles. (2) (3) (4) There are also documented experimental infections 
of Leishmania in marsupials. (5)  
Leishmania was first noticed by Cunningham in 1885 and later described by 
Leishman and Donovan in 1903. (Reviewed in (1))  Leishmaniasis is the disease caused by 
these parasites in the host after infection by the sandfly vector.  This mainly zoonotic disease 
is endemic in tropical and sub-tropical regions of the world.  In 1993, the World Health 
Organization (WHO) estimated at least 3-5 million clinical cases among 12 million infected 
individuals living in endemic areas (Reviewed in (1)).  In recent years, the incidence of 
leishmaniasis cases has increased and extreme importance had been paid to AIDS patients, 
because of opportunistic infections of Leishmania that may arise and affect the well-being of 
these patients. (1) (6)  
Evolutionary overview of the Leishmania genus reveals a neotropic (New World) 
origin and a divergence between the Leishmania complexes (i.e. L. major, L. mexicana, L. 
donovani and L. viannia.) (7) The cutaneous disease-causing species are as phylogenetically 
different from one another, as they are from those causing visceral disease. (7) Each 
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Leishmania species have different epidemiological features involving a considerable range of 
reservoir hosts and insect vectors. Furthermore, within the cutaneous-causing Leishmania 
species there are many immunogenetic and virulent differences between the L. major 
complex and the L. mexicana/ L. amazonensis complex.   
Leishmaniasis infection occurs in three different forms: the cutaneous, muco-
cutaneous and the visceral form, the latter of which is considered a very severe systemic 
disease.  The manifestations of leishmaniasis depend on the species. of Leishmania involved 
in the infection, and the host immune response to the parasite.  
The cutaneous forms of leishmaniasis are classified as either local cutaneous 
leishmaniasis (LCL) or diffuse cutaneous leishmaniasis (DCL).  LCL is described as a self-
limiting skin lesion developed at the area of the sandfly bite, whereas DCL is a collection of 
multiple chronic lesions spreading farther from the lesion of the original inoculation site. (8) 
LCL lesions usually take months to heal, (8) while DCL lesions do not heal as well as LCL 
lesions.   
Mucocutaneous leishmaniasis (ML), also known as espundia, is closely associated 
with L. braziliensis. ML causes skin ulcers that heal or remain active as lesions affecting 
mucous tissue of the nose and mouth. (8) These lesions can even appear years after the initial 
lesion had healed and usually it is associated with massive tissue destruction.  In visceral 
leishmaniasis, the parasite homes to the liver, spleen and bone marrow. (8) If left untreated, it 
could result in hepatomegaly and splenomegaly, which will be fatal for the patient. (1) 
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Life cycle 
Leishmania are digenetic organisms.  Its life cycle involves two morphologically 
different forms; one form (amastigotes) inhabiting the vertebrate host and the other 
(promastigotes) survives within an invertebrate vector (female sandfly).  The infected sandfly 
transmits the parasites between vertebrates when it feeds on blood. 
Inside the female sandfly’s midgut and foregut, Leishmania parasites grow as motile 
flagellated promastigotes.  Promastigotes within the sandfly's midgut undergo a series of 
developmental stages that helps them survive in the gut environment.  It is during this 
process called metacyclogenesis when parasites progress from immature procyclic 
promastigotes inhabiting the midgut area to highly infective and mature metacyclic 
promastigotes attached to the insects’ esophagus and pharynx.   
The known events accompanying the metacyclogenesis are mostly associated with 
changes in the structural and biochemical aspects of the promastigotes cell surface.  This 
surface is covered by a glycocalix coat, which is composed of various surface molecules, 
from which the most abundant of such molecules is a glycolipid complex known as 
lipophosphoglycan (LPG).  During metacyclogenesis, LPG undergoes modifications in 
glycosylation that lead to the elongation of its backbone, causing thickening of the parasites' 
glycocalix. (9)  
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The importance of the metacyclogenesis was revealed when it was demonstrated that 
promastigotes taken from sandflies 3 days after infection are avirulent, whereas 
promastigotes taken 7-8 days old were infective (Reviewed in (1), (10)).  
Parasite vs. Host Immune Response 
Establishing infection 
Inside the host blood stream, Leishmania promastigotes must avoid the lytic events 
coordinated by the serum complement system.  Metacyclic promastigotes within the host 
serum manage to avoid complement lysis and use the complement system activation to their 
advantage.  To do so, they make use of molecules and proteins (i.e. LPG and gp63) that are 
modified on their membrane after metacyclogenesis.   
LPG allows the parasite to resist complement-mediated lysis within the host tissue.  
The elongation of the LPG molecules and thickening of the glycocalix in L. major and L. 
donovani metacyclics promastigotes prevents insertion of the membrane attack complex 
(MAC). (11) L. donovani uses LPG elongation to avoid C3bi deposition and therefore, avoids 
formation of the C5 convertase, important for MAC formation. (11) (12) LPG has also been 
shown to be important for parasite survival, as it modulates nitric oxide production (13), 
inhibits apoptosis (14), delays phagolysosomes maturation (15) and inhibits macrophage 
signal transduction. (16) 
Gp63, another important molecule up regulated during metacyclogenesis, also helps 
avoiding complement-mediated lysis by cleaving C3b to an inactive form termed C3bi. 
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(Reviewed in (17)) Binding of the mannan-binding protein to the mannose-terminating 
oligosacharides in the LPG is also an alternative way for complement activation. (Reviewed 
in (17)) It allows C3 convertase to attach to the parasite cell surface and enhances the 
formation of C3b. (Reviewed in (17)) 
Parasite Uptake 
Entrance of the parasite to the host cell is a receptor-mediated process.  For 
macrophage phagocytosis, Leishmania takes advantage of the previously described 
opsonization by C3b and C3bi, which will respectively bind to the CR1 and CR3 receptors 
on the macrophage surface. (18) (19) (20) LPG and the major protease gp63 on the 
promastigotes surface serve as ligands for attachment to CR1 and CR3 receptors. (21) CR1 
and CR3 mediated phagocytosis may be mostly beneficial to the parasite, since it inhibits 
nitric oxide (NO) production and therefore, the parasites avoids being killed by NO oxidative 
effects. (12) Also, CR3-mediated phagocytosis seems to inhibit IL-12 induced cell-mediated 
immunity. ((12), (22), reviewed in (17))  
Receptor-mediated parasite internalization has also been documented for the 
amastigotes form of Leishmania.  For instance, it has been shown that after immunoglobulin 
opsonization, both L. major and L. mexicana amastigotes make use of Fc receptors as means 
of entering macrophages. (17), (23) 
Inside the host cell, promastigotes are exposed to new environmental cues that trigger 
their transformation to intracellular amastigotes.  During this transformation process, the 
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parasite will undergo loss of the flagellum, closing of the flagellar pocket, drastic reduction 
of size and major changes in gene expression. (Reviewed in (1)) 
The mechanisms in the formation of parasitophorous vacuole (PV) by Leishmania 
species are still unknown.  However, it is known that amastigotes survive intracellularly 
within a membrane-bound phagosome, which will in turn be modified by fusion of secondary 
lysosomes to a PV. (24) The PV presents a highly hydrolytic and acidic environment, where 
amastigotes survive due to their acquired resistance to low pH and their alleged shift to 
anaerobic respiration. (Reviewed in (1) (24)) PV’s produced by different Leishmania species 
share many characteristics, but differ in others.  For example, L. amazonensis and L. 
mexicana produce large PV containing many amastigotes arranged around the periphery and 
attached to the membrane, while L major and L. donovani produce small PVs with little 
space around the amastigotes.  (Reviewed in (1))   
 DC and Leishmania 
Dendritic Cells 
It has been demonstrated that the other host cell infected by Leishmania is dendritic 
cells (DC). (25) DC are potent antigen presenting cells (APC) with a unique ability to induce 
a primary immune response. (26) They are produced in the bone marrow (BM) by progenitor 
cells.  DCs exit the BM as circulating immature precursor cells and then home to non-
lymphoid tissues where they will remain as immature cells with a highly phagocytic capacity. 
(Reviewed in (26))   
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Immature DC are efficient phagocytic cells.  They can capture antigen in many 
different ways (i.e. endocytosis mediated by C-type lectin receptors or Fc g receptors, 
macropinocytosis, or phagocytosis. (Reviewed in (26)) 
DC Leishmania infection 
Soon after the uptake of a pathogen or foreign Ag, DCs will get activated in a process 
called "maturation".  Maturation is often associated with certain morphological events such 
as down-regulation of antigen-capture and phagocytic capacity (27) (25), upregulation of 
costimulatory molecules CD40, CD58, CD80, and CD86 (28); shift of lysosomal 
compartments with downregulation of CD69 and upregulation of DC-LAMP, enhanced 
cytokine expression (29), and change in MHC class II compartments.   
Leishmania internalization by DC is assumed to take place in the same way as in 
macrophages.  Like macrophages, DCs are known to express CR1 and CR3 receptors on their 
cell surface, receptors used by macrophages for parasite internalization.  However, in humans 
it has been shown that a surface C-type lectin receptor (DC-SIGN) may play an important 
role on parasite uptake by immature monocyte-derived DC isolated from human peripheral 
blood. (23), (30), (31) Some studies reveal DC-SIGN as a receptor for promastigotes and 
amastigotes of both visceral (L. infantum) and New World cutaneous (L. pifanoi) Leishmania 
species, where such interactions seem to be LPG independent. (30) 
After the Leishmania uptake, DCs will undergo a maturation process as they migrate 
towards the draining lymph node.  Within the lymph node, DC home to the T cell rich areas 
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where they present Ag via MHCII engaging the T cell receptor (TCR) of specific T cells. 
(Reviewed in (26))   
DC-T cell interaction helps T cells differentiate between a Th1 and Th2 phenotype.  
This interaction is a two-step process where the first signal is the recognition of the MHC 
molecule carrying the pathogen specific peptide by the TCR. (Reviewed in (26)) The second 
step is the activation of T cells through interaction of costimulatory molecules expressed on 
DCs, such as CD86, and its respective ligands expressed by T cells. (Reviewed in (26)) 
Activated T cells can further stimulate naïve DC through the CD40 ligand (CD40L)-CD40 
interaction. The CD40L-CD40 signaling increases expression of CD80/CD86 on DCs and is 
essential for cytokine release (TNF, chemokines, and IL-12). (32) 
Another important role of mature DCs in the activation of a cell-mediated immune 
response is their ability to produce cytokines.  As soon as they are activated, mature DCs can 
secrete IL-12 which in turn induces T cells to produce IFN-g.  IFN-g mediates NO-killing by 
infected macrophages. (33)  
The immune system owns a vast arsenal of resources that work together to inhibit the 
survival chances of Leishmania parasites.   Nevertheless, it is the evasion of the immune 
activation that allows many Leishmania species to survive within a host.  For example, it has 
been shown that L. major parasites are able to avoid the Th1 response as long as 4-5 weeks 
soon after inoculation. (34) Within this period of time, parasites are able to undergo a 
prolonged phase of amplification in the skin until the infiltration of neutrophils, 
9 
  
macrophages, and eosinophils to the dermis, which coincides with parasite killing. (34) 
MIP 3b  and CCR7 interaction 
The basis and effectiveness of the cell-mediated immune protection depends 
summarily on the organization of the immune system for directing cellular migration to 
lymphatic tissues as well as to the site of infection.  For that reason, DC migration towards 
the lymph node is essential for the priming of the immune response.  Many factors coordinate 
DC migration; (cytokines, adhesion molecules, and chemokines) in particular chemokines.  
Chemokines are a large family of 8-10 kDa proteins capable of leukocytes activation 
regulating DC migration (36). They are divided into four families, alpha (CXC), beta (CC), 
CX3C-families, and a final group lacking the first two cysteines (C-family) (36). Chemokines 
interact with seven-transmembrane-domain receptors from the heterotrimeric G protein-
coupled receptor superfamily (35), (36). This chemokine-receptor interaction produces a 
signal via G proteins (36), which in turn activates different signal transduction cascades (35). 
The activated signal transduction cascade depends on which chemokine-receptor interaction 
is engaged (35). 
Chemotaxis is the most common response to chemokine stimulation (35), and it refers 
to the movement of a cell towards a gradient concentration.  DC mobility is dependent upon 
the interaction of chemokines with receptors expressed on the DC surface.  Immature DCs 
express receptors (CCR1, CCR5, CCR6, etc.) that respond to many C-C and CXC 
chemokines. (36) For example, chemokine MIP-3a (CCL-20) plays an important role on 
recruitment of immature DCs to the site of inflammation.  MIP-3a has been found to be 
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constitutively expressed on human skin and upon activation by inflammation it is induced in 
various cell types (36),  (37).  This chemokine is responsible for mediating migration of 
immature DC to the site of inflammation via CCR6 interaction (36). CCR6 is a member of 
the seven-trans-membrane family of chemokines receptors, which is expressed on immature 
DCs. (36) Upon maturation, DCs lose responsiveness to MIP-3a as a result of down-
regulation of CCR6 expression (36).  
Concomitantly with the unresponsiveness to MIP-3a, another important event during 
DC maturation is the upregulation of CCR7 expression. (36) CCR7 is also highly expressed 
on naïve T cells (36) and mediates cellular migration towards the lymphatics through 
interaction with the chemokines SLC (6Ckine, CCL21) and MIP-3b  (ELC, CCL19). (36) 
SLC is constitutively expressed by stromal cells in the T cell rich areas of the secondary 
lymph nodes, endothelial cells of lymphatic vessels and of high endothelial venules (HEV).  
In mice, SLC not only interacts with T cells through CCR7, but also through CXCR3.  The 
expression of CXCR3 however has not been documented on DC.  MIP-3b  is produced by 
mature DCs, and also by stromal cells present in the T cell zone area. (36) The signaling 
pathways that emanate from CCR7 interaction have been recently characterized and are still 
under scrutiny. 
Due to the important role that CCR7 plays in DC migration, researchers had focused 
their attention towards finding any correlation between DC migration patterns and CCR7 
expression of those migrating cells.  On experiments conducted with DC infected with L. 
donovanni, it was found that infected cells not only showed an impaired migration, but also 
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these cells displayed a reduction of CCR7 expression independent from DC maturation. (38)  
In addition, it has been reported that in the absence of CCR7, DCs become unresponsive to 
both MIP-3ß and SLC.  
 
Figure 1. BM-DC migration in responses to MIP -3b after infection with Leishmania. After Ag 
uptake or infection, BM-DC up-regulates expression of CCR7 receptor.  The CCR7 
receptor mediates the infected cell migration from the infected tissue towards the 
nearest draining lymph node via the receptor’s interaction with MIP-3ß produced by 
the lymph node.  Once inside the lymph node, the infected DC will present Ag to the 
Th0 cells which in turn proliferate as Th1 cells. The Th1 cells leave the lymph node 
and migrate towards the infected tissue.  
CCR7 initiates signal transduction through activation of members of the Gi family of 
heterotrimeric G proteins (35). When both SLC and MIP-3b  bind to CCR7, the 
heterotrimeric G protein is activated and dissociates into Ga and Gbg subunits (37). The 
recently released Ga subunit inhibits adenylyl cyclase (38), and is known to play an 
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important role in cellular migration.  Recently, the Ga subunit has been reported to activate 
Src family kinases (39).  This Ga subunit interaction with Src can be of great significance 
considering the high structural homology of the kinase domain among the Src-related 
enzymes, thus implying the possibility that Ga subunit may activate other members of the 
Src family (40).  However, Ga itself is not sufficient to mediate cellular migration.  Instead, 
it has been proposed that the Gbg subunit, also released from the Gi-coupled receptor, is the 
essential factor mediating cellular migration (35). 
Further evidence from a study with D. discoideum supports the crucial role of Gbg 
subunit in the regulation of chemotaxis (35).  This study demonstrated that after chemotactic 
stimulation the Gbg subunit is distributed asymmetrically with a higher concentration at the 
anterior end of the amoeba (35), (41).  The Gbg dimer directly activates phospholipase Cb2 
(PLCb2) (38), PLCb3, and phosphatidylinositol 3 kinase (PI3K) (42).   
The activation of the PLCb  isoenzymes leads to the formation of inositol-1, 4, 5-
triphosphate (InsP3) and to a transient increase of the concentration of intracellular free 
calcium (38), (35).  In a study involving neutrophils of mice lacking the genes encoding 
PLC-b2 and PLC-b3, it was demonstrated that chemokine- induced calcium elevation was 
suppressed, thereby supporting the idea that only these PLC-b  isoforms are activated by 
chemokines in immune cells (35). This study also revealed that intracellular elevation of 
calcium is not necessary for chemotaxis, since these neutrophils did not show any defects in 
chemokine-stimulated migration (35). Gbg induced-activation of the PLC isoforms also leads 
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to formation of diacylglycerol and subsequent activation of protein kinase C (PKC) (35). 
PKC activation contributes to receptor phosphorylation, which will in turn leads to 
desensitization.  With desensitization, CCR7 will diminish responsiveness towards repeated 
or prolonged exposure to MIP-3b  and/ or SLC.  This process requires the phosphorylation of 
the receptor tail by G protein- coupled receptor kinases to promote binding of b  arrestins.   
Susceptibility 
In the murine model of Leishmania infection, susceptibility to infection depends on 
the species of Leishmania parasite involved and the genetic background of its host.  In this 
section the immunological differences between each of the Leishmania complexes discussed 
in order to facilitate the understanding of the immunological predicament that is represented 
by each of the major complexes in the Leishmania genus; L. major, L. mexicana complex and 
the L. donovanni complex (including L. amazonensis).   
Susceptibility to L. major infections is often associated with an early dominance of an 
IL-4-driven Th2 response, whereas resistance correla tes mostly to an IL-12-driven, 
Interferon-g -dominated Th1 response that promotes healing and parasite clearing (Reviewed 
in (44)).  During L. major infection a single T cell epitope derived from Leishmania homolog 
of receptors for activated C kinase (LACK) antigen, induces rapid IL-4 by Vß4Va8 CD4 T 
cells, renders T cells unresponsive to IL-12 and promotes lesion development (45). Mice 
exhibiting a Th2 phenotype (BALB/c, and SWR/J) develop progressive non-healing 
cutaneous lesions during L. major infections, whereas mice of a Th1 background (C3H, 
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CBA, C57BL/6, and C57BL/10) are resistant.   
Although the majority of the studies using L. major have demonstrated a major role 
for an IL-4-induced Th2 response in disease susceptibility, (7) other studies have cast 
uncertainty to whether early IL-4 production is an indicator of susceptibility to L. major (46).  
These studies demonstrate an IL-4 independent mechanism for susceptibility, which may 
imply a possible role for IL-13.  However, the inability of BALB/c IL-4Ra-/- mice to interact 
with cytokines IL-4 and IL-13 did not protect them to the same degree as the resistant 
wildtype C57BL/6 (47), suggesting a possible role for other effector mechanisms in disease 
exacerbation (7).   
The IL-4-dependent susceptibility was further supported by studies with BALB/c 
mice that were treated at the time of infection with anti-IL-4 monoclonal antibody or in IL-4-
deficient BALB/c mice, both showed resolution of infection with L. major. (Reviewed in 
(44))  These studies suggested that inactivation or inhibition of IL-4 production at early 
stages of infection were beneficial for the susceptible strains of mice to clear L. major 
infection. 
Recent data had revealed that perhaps IL-4 and other major Th2 cytokines are not 
sufficient, and at some cases, it is not necessary for susceptibility in L. major infections.  The 
sustained production of major Th2 cytokines does not impede the development of a Th1 
response. (Reviewed in (44)) It seems that the defect relies more on the inability of producing 
IL-12, rather than the production of Th2 cytokines at the early stage of infection.  The defect 
on the TH1 response may be due to different factors, such as unstable expression of IL-
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12Rb2. 
The relevance of the early production of IL-4 as a factor leading to susceptibility is 
still under scrutiny, since it has been shown in recent studies that levels of IL-4 after 
Leishmania infection are the same in both resistant and susceptible strains of mice.  
(Reviewed in (44)) Furthermore, when treated with IL-4 injections (Reviewed in (44)) or 
anti-IL-12 antibodies (48) at the time of parasite challenge, C3H mice display a strong, but 
transient Th2 response, an event that does not reverse the normal resistant phenotype of these 
mice.  However, if the anti-IL-12 antibody treatment is continued in resistant mice for days 
after parasite inoculation, they will fail to control the disease, thus suggesting a more 
significant role of IL-12 in parasite clearance. (Reviewed in (44)) 
The cytokine IL-4 plays a major role in promoting non-healing murine L. mexicana 
infections in susceptible mouse strains.  It has been shown that the non-healing disease 
phenotype after L. mexicana infection is dependent on an IL-4-derived lymphocyte and that 
IL-4-deficient splenocyte–reconstituted SCID mice heals (49), (50). In another study it was 
demonstrated that after L. mexicana infections, mice lacking IL-4 or STAT-6, which is 
involved in IL-4 signaling, will acquire a Th1 response and fail to develop a lesion (49), (51). 
Although IL-4 has been singled out as an important cytokine for susceptibility to L. mexicana 
infections; recent studies have suggested an important role for IL-13 for maintenance of 
chronic infection (52), (53).  
Susceptibility in the L. amazonensis and L. mexicana systems differs greatly from 
what is observed in the L. major model.  Some studies have shown that IL-4 and signaling 
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via STAT-6 play an insignificant role in non-healing disease (45), (49). This was 
demonstrated in a study where IL-4-deficient C57BL/6 mice still developed lesions after L. 
amazonensis infection (54).  In the L. amazonensis murine system, not only are mice from a 
BALB/c background susceptible to infections with L. amazonensis and L. mexicana, but also 
mice that are resistant to L. major infections (C3H, C57BL/6 and C57BL/10) (54), (55).  
The susceptible phenotype expressed by L. major-resistant mice strains after L. 
amazonensis may not be associated with a Th2 response, since these mice are known to 
produce low levels of IL-4 after infection.  Susceptibility was associated with defective IL-12 
receptor expression by CD4+ T cells after infection with L. amazonensis which was due to 
reduced IL-12Rb2 expression, a fundamental chain that works conjunctively with IL-12Rb1 
for a functional IL-12 receptor (54). The importance of expression of a functional IL-12 
receptor was demonstrated when C3H and C57BL/6 mice infected with L. amazonensis still 
displayed a persistent chronic infection even after administration of exogenous IL-12 (54). 
The data supports the hypothesis that susceptibility and disease exacerbation in L. 
amazonensis is due to a failure to promote a Th1 response rather than the development of a 
predominant Th2 response (54). These results also suggest that L. amazonensis parasites have 
mechanisms to control the immune response of the host helping the parasite promote a 
chronic infection and evade parasite killing (54).   
The known immunomodulatory effects of IL-10 have implied a possible role for this 
cytokine in mice susceptible to L. amazonensis and L. mexicana infections.  Studies 
conducted on IL-10-deficient mice from a BALB/c background infected with L. amazonensis 
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or L. mexicana revealed that, although they fail to control the progression of infection, they 
did exhibit lower level of infection when compared to wild type BALB/c mice (56). 
Furthermore, when compared to wild type BALB/c mice, cells of IL-10-deficient mice 
infected with L. amazonensis and L. mexicana express higher levels for IL-12p40 and IL-
12Rß2 mRNA and an increased IFN-gamma and NO production, indicating promptness 
towards an enhancement of a Th1 response (56).  
Similar stud ies were also conducted on C57BL/6 IL-10-deficient mice infected with 
L. amazonensis.  On those studies, parasites were shown to persist even in the presence of an 
improved Th1 response early during the infection that was characterized by higher levels of 
IFN-g and IL-12 p40, when compared to C57BL/6 wild type mice (57).  However, during 
chronic infection there was no enhanced T cell response, yet lower parasite load, suggesting 
the role of IL-10 has more significant effects at the level of macrophage activation rather 
than influencing the T cell response (57).  Taken together, all these data seem to imply that 
early production of major Th2 cytokines during chronic infections of L. amazonensis and L. 
mexicana have a significant negative impact on the development of a Th1 response.  
However, the mere exclusion of these cytokines during early stages of infection does not 
necessarily lead to resolution of the infection. 
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Hypothesis 
Leishmaniasis, as many other infectious diseases, has proven to be a fascinating 
model to study the struggle between the host defense system and the mechanisms deployed 
by the parasite to evade them.  Although infections with certain cutaneous Leishmania 
species, like L. major, present pathologies that are cleared after couple of months, infections 
with other species like L. amazonensis can persist.  As mentioned before, the healing of L. 
major infections in the mouse is closely associated to the development of a strong and 
effective Th1 response.  Thus, failure to mount a proper Th1 response is believed to lead to 
susceptibility of L. major infection.  However, this dogma does not describe the pathological 
profile displayed during L. amazonensis infection.  The development of a strong Th1 
response is not enough to clear L. amazonensis infection.  Indeed, many different factors are 
believed to lead to susceptibility after L. amazonensis infection.  One such factor suggests 
that susceptibility to L. amazonensis is due in part to defective antigen presentation by 
infected APC.  In fact, a recent paper indicates that even when parasites can be detected at 
the lymph nodes a few hours after infection, none of the DC emigrants from the skin 
contained parasites (60).  In addition, after L. major infection of C57BL/6 resistant mice with 
low parasite dose into a dermal site, there was a prolonged silent phase of parasite 
amplification in the skin, lasting 4-5 weeks, before the onset of lesions and immunity (27). 
These examples show that somehow the parasites are evading an early DC recognition and 
seem to be invisible to the host’s immune defense.  Yet more surprising data comes from a 
study that showed that after 18hr incubation with stationary phase L. mexicana 
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promastigotes, the majority of a population of BM-DC grown for 7 days still displayed an 
immature profile. (60)  Same results were observed after latex beads uptake by BM-DC, thus 
suggesting the existence of a Leishmania silent infection.  All of these new data suggest that 
either Leishmania parasites are avoiding detection by DC or that it may hinder DC activation 
during infection.  
Given the extreme importance of DCs as major APC and their influence in proper 
activation of T cells towards a protective Th1 response, and major producers of IL-12, we 
suggest that one of the many factors contributing to L. amazonensis susceptibility may be 
linked to the fact that Leishmania parasites tend to delay DC maturation.  We propose that 
such defect may alter DC’s migration ability by altering DC responsiveness to MIP-3b , thus 
limiting DC recruitment at the nearest draining lymph node for Ag presentation and T cell 
activation.  With this study we intended to test the hypothesis that murine BM-DCs infected 
with L. amazonensis amastigotes display an impaired migration response towards MIP-3b  in 
vitro.  Simultaneously, we wanted to test if a defect in migration might be correlated to a 
down-regulation or impaired up-regulation of CCR7, an important marker for DC maturation 
and also the chemokine receptor for MIP-3b .  In addition, the levels of IL-12 p40 production 
will be measured in order to analyze DC maturation and the level of activation.   
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2. MATERIALS AND METHODS 
Parasite 
Leishmania amazonensis (MHOM/BR/00/LTB0016) and Leishmania major 
(MHOM/IL/80/Friedlin) promastigotes were grown to stationary phase culture and used for 
experiments.  Promastigotes were grown in vitro at 27°C in Grace's medium (Life 
Technologies, Grand Island, NY), containing 20% heat inactivated fetal bovine serum, 2 mM 
glutamine, 100U/ml of penicillin, and 100 mg/ml streptomycin.  Stationary phase parasites 
were washed by centrifuging twice at 3000 rcf for 15 minutes in PBS before they were used 
for infection.  Promastigotes were counted under the microscope, using a hemacytometer.  
The amastigote form of Leishmania was collected from severe combined immuno-
deficient (SCID) C3HeB/FeJ mice (The Jackson Laboratory, Bar Harbor, Maine) infected 
with 10-20 x 106 stationary phase promastigotes subcutaneously in the left hind footpad.  
After developing a lesion, SCID mice were euthanized and the left hind foot was collected 
and cleaned with 70% ethanol for 3 minutes before peeling of the skin.  Soon after that, the 
foot was then homogenized using a Tenbrock homogenizer and the suspension was 
centrifuged at 180 rcf for 10 minutes to get rid of excessive debris.  After centrifugation, the 
supernatant was transferred to different sterile tube and then centrifuged at 3000 rcf for 15 
minutes.  The pellet obtained after the second centrifugation was resuspended on 1 ml of 
PBS.  Viable amastigotes were counted under the fluorescent microscope with a 
hemacytometer using carboxy fluorescein di-acetate and propidium iodide exclusion. 
21 
  
Isolation and Culture of Bone Marrow-Derived Dendritic Cells 
Bone marrow-derived dendritic cells (BM-DC) were cultured in vitro following a 
method adapted from Lutz et al. (ref) Bone marrow from 4-10 weeks old male C3HeB/FeJ 
mice was extracted and 4 x106 cells were plated with 10 ml of DC-medium.  DC-medium is 
composed of RPMI 1640 (Sigma, St. Louis, MO) and complemented with 10% Fetal Bovine 
Serum (Atlanta Biologicals, Norcross, GA), 100 U/ml penicillin (Cellgro, Herndon, VA), 
100 mg/ml streptomycin (Cellgro, Herndon, VA), 2mM L-glutamine (Cellgro, Herndon, VA), 
50 mM Beta-2-Mercaptoethanol (Cellgro, Herndon, VA) and 10 ng/ml of murine granulocyte 
macrophage-colony stimulating factor (GM-CSF) (PeproTech Inc. Rocky Hill, NJ).  
On day 3 of culture, an additional 10 ml of DC-medium containing10 ng/ml of 
murine GM-CSF was added to the culture.  At day 6, 10 ml of the culture supernatants were 
harvested, centrifuged, and the pellet resuspended in fresh 10 ml of DC-medium containing 
10 ng/ml of GM-CSF, before it was added to the BM-DC culture. 
On day 8 of culture, non-adherent cells were collected and centrifuged at 250 rcf for 
10 minutes.  Viable cells were counted using Trypan blue exclusion (Bio Whittaker, 
Walkersville, MD). 
Two tubes containing 0.5 x 106 cells were used for CD11c staining.  First, tubes were 
washed once with 2ml of FACS buffer at a speed of 250 rcf for 10 minutes.  After 
centrifugation, supernatant was discarded and 10 ml of Fc block was added to each tube.  Fc 
block is composed of 10% Fcg III/II / 2.4G2 antibody (Pharmingen, San Diego, CA) and 
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90% of rat IgG (Sigma, St. Louis, MO) in a concentration of 1mg/ml.  After vortexing both 
tubes, 0.1 mg of CD11c antibody was added to one tube while the other tube received 0.1 mg 
of the hamster IgG1 l isotype.  Tubes were left on ice in the dark for 30 minutes and then 
washed in 2ml of FACS buffer.  Cells were analyzed by flow cytometry, performed using a 
FACScan (Becton Dickinson, San Jose, CA) and Cell Quest (Becton Dickinson, San Jose, 
CA) for analysis.   
Maturation state of the BM-DC was analyzed by FITC dextran and FITC albumin 
uptake.  Cells were incubated with 1mg/ml of FITC dextran (Sigma, St. Louis, MO) and 0.5 
mg/ml of FITC albumin (Sigma, St. Louis, MO) for one hour at 4°C or 37°C.  
Approximately, 45-65% and 35-55% of the 8-day-old BM-DCs were FITC dextran and FITC 
albumin positive, respectively. 
Cell Treatment 
BM-DC's were infected with L. amazonensis and L. major amastigotes or 
promastigotes at 1:3 ratio and were incubated at 34°C for a 24-hour period. As a positive 
control, BM-DCs were stimulated with 50ng/ml LPS L-5014, lot 60k4107 (Sigma, St. Louis, 
MO). To enhance stimulation, LPS-treated cells received either 1mg/ml of anti-CD40 low 
endotoxin/ no azide (Pharmingen, San Diego, CA) or 0.25 mg/ml CD40L (PeproTech Inc. 
Rocky Hill, NJ) for 24hrs as well.   
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Migration Assay 
DC migration assay was performed in 6.5 mm diameter 24-well Transwell culture 
plates containing 8 mm pore size inserts. (Corning Costar Inc. Corning, NY)  Twenty-four 
hours after treatment, cells were rested on ice for 45 minutes, and then washed at 250 rcf for 
10 minutes.  After washing, cells were counted by Trypan blue exclusion and 1 x 105 DC 
were collected from each treatment and added to the Transwell inserts in 100 ml of fresh DC 
medium.  Cells contained in the Transwell inserts were rested above 600ml of DC medium in 
bottom chambers at 37°C for 1 hr.  After incubation, inserts containing the cells were 
transferred to a new Transwell plate containing 600 ml of fresh DC medium with or without 
50ng/ml of MIP 3b  (PeproTech Inc. Rocky Hill, NJ) in each bottom chamber.   
After the final incubation at 37°C for 1 hour, BM-DC's that had migrated to the 
bottom chamber were harvested and collected in pre- labeled tubes.  The 600ml of DC-
medium contained at the bottom of each well were split in half; around 300 ml were fixed for 
cytospin analysis and the remaining 300 ml of medium were used for flow cytometry 
analysis.  After harvesting the cells, all wells were washed with 1 ml of DC-medium to 
collect any remaining cells that were left.  This additional medium was eventually collected 
and added to the respective tubes containing the original 600 ml of DC-medium with 
migrated cells.  All tubes were centrifuged at 250 rcf for 10 minutes.  After centrifugation, 
supernatants from all tubes were discarded, and cells were washed twice in 2 ml FACS 
buffer.  After final centrifugation, cells were fixed with 200 ml of 1% paraformaldehyde or 
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resuspended on 200 ml of FACS buffer for analysis.  
Flow cytometry analysis was performed using a FACScan® (Becton Dickinson, San 
Jose, CA) machine and Cell Quest (Becton Dickinson, San Jose, CA) software for analysis.  
To facilitate counting of the cells, 1 x 105 surfactant- free white sulfate latex beads were 
added to each tube containing the cells recovered after migration at the time of analysis.  
Each tube was vortexed before analysis, in which beads and cells were gated at different 
regions on the forward-scatter side-scatter dot plot.  FACScan® analysis was set to stop 
counting after collecting 1 X 104 events from the beads gated region.  Assuming the 
proportion of the number of beads counted by flow cytometry relative to the total number of 
beads added to each tube was equal to the proportion of the number of cells counted relative 
to the total amount of migrating cells, we therefore calculated migration pattern with the 
following equation: X=C/(A/B).  The number of migrating cells (X) was determined from the 
ratio of the number of cells counted (C) and the proportion of beads counted (A) over the 
number of beads added (B).   
IL-12 p40 ELISA 
Supernatants collected 24 hr after infection and before the migration assay were used 
to detect levels of IL-12 p40 by enzyme-linked immunosorbent assays (ELISA).  All 
supernatants were stored at –20°C.  IL-12 p40 ELISA was performed using 96-well plates 
that were coated with 2mg/ml of rat purified anti IL-12 p40/p70 (Pharmingen, San Diego, 
CA) diluted in 100 ml of PBS, over night at 4°C or at 37°C for 2 hours. After incubation, 
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plates were brought to room temperature and 150 ml of ELISA blocking buffer (5% of 
newborn calf serum in 1X PBS) was added to each well on the plates and incubated at 37°C 
for one hour.  Following the 1-hour incubation, plates were washed 5 times in washing buffer 
(1 X PBS/0.05% Tween 20).  Then 100 ml of blocking buffer was added to each well, except 
for the first well in the columns chosen for the IL-12 p40 standard, which received 180 ml.  
From supernatants collected from each sample 24-hour post infection, 33.5 ml were added to 
the first row of wells and then diluted 1:4 for a total of 4 wells per sample, carefully mixing 
the sample every time it was diluted.  For the IL-12 standard, 20 ml of 100 ng/ml were added 
to the wells from the first row and diluted 1:2 for a total of 8 wells.  Plates were incubated at 
37°C for 2-4 hours or stored at 4°C overnight. 
Plates were once again washed in washing buffer for five times.  Then, 100 ml of 
biotinylated anti IL-12 (Pharmingen, San Diego, CA) diluted to 0.25 mg/ml in blocking 
buffer was added to each well for an hour incubation at 37°C.  Plates were then washed 10 
times in washing buffer and then incubated at 37°C for 1 hour with 100 ml of peroxidase-
conjugated streptavidin (Jackson ImmunoResearch Laboratories, West Grove PA) diluted to 
0.5 mg/ml in blocking buffer.  After incubation, plates were washed 10 times in washing 
buffer before adding 100 ml to each well of ABTS peroxidase substrate (Kirkegaard & Perry 
Laboratories, Gaithersburg, MD) to each well.  Plates were read using SOFTmax pro 3.1.1 
software and E max machine.   
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Intracellular CCR7 Flow Staining 
From each treatment group, three pre- labeled tubes containing 0.5 x 106 BM-DCs 
each were collected for CCR7 staining.  Each of the three tubes from each group represents a 
control for the staining, isotype control, antibody control and antibody and blocking peptide 
control.  All tubes were initially centrifuged at 250 rcf for 10 minutes at 4°C, fixed with 200 
ml of 1 % paraformaldehyde and kept overnight at 4°C.    
The following day, tubes were resuspended in 2 ml of FACS buffer and centrifuged at 
800 rcf for 10 minutes at 4°C (all centrifugations for CCR7 staining followed the same 
parameters).  Cells were centrifuged and resuspended in 1 ml of FACS buffer + 0.1% 
saponin, then centrifuged again and the supernatants decanted. Cells were resuspended in the 
remaining volume of supernatant (approximately 100 ml), to which 10 ml of Fc block was 
added.  Soon after vortexing, 0.2 mg/ml of primary CKR7 antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) and goat IgG (Jackson ImmunoResearch Laboratories, West 
Grove PA) was added to the antibody controls and isotype control respectively.  The 
antibody and blocking peptide control from each treatment received 10 ml from a master mix 
prepared with 0.2 mg/ml of primary CKR7 antibody and 1mg/ml blocking peptide (Santa 
Cruz Biotechnology, Santa Cruz, CA). Tubes were kept at 4°C for 30 minutes. 
Tubes were resuspended in 2 ml FACS buffer + 0.1 % saponin for centrifugation.  
After discarding supernatants, 0.15 mg of FITC-conjugated donkey anti-goat IgG (Jackson 
ImmunoResearch Laboratories, West Grove PA) was added to each tube and then incubated 
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for 30 minutes at 4°C.  Then, tubes were centrifuged with 2ml FACS buffer + 0.1 % saponin 
again and after decanting the supernatant, and resuspended in the residual volume of 
supernatant, 10 ml of a 1:1000 dilution of Streptavidin PE (Pharmingen, San Diego, CA) was 
added to each tube, and incubated at 4°C for 30 minutes.  Each tube was resuspended in 2 ml 
of FACS buffer and centrifuged again.  After centrifugation, all tubes were resuspended in 
200 ml of FACS buffer for FACScan analysis. 
Real time PCR 
RNA extraction was performed on uninfected BM-DC, cells either infected with 
Leishmania for 24 hours or treated with LPS/anti-CD40 or CD40L, which were previously 
stored on 50 ml of DC-medium at -80°C.  Cells were lysed in 1ml of TRIzol (Invitrogen Life 
Technologies, Carlsbad, CA).  After dissolving any sediment at the bottom of the tube with 
TRIzol, DNA was sheared by forcefully expelling the lysate approximately 5 times through a 
26-G needle with a 1-ml syringe.  Homogenized samples were rested 5 minutes at room 
temperature for complete dissociation of nucleoprotein complexes.  After resting, each 
sample received 200 ml of chloroform per ml of TRIzol and shaken vigorously by hand for 
15 seconds.  Samples were again rested at room temperature for 3 minutes and later 
centrifuged at 12,000 X g for 15 minutes at 4°C.  Centrifugation caused the samples to 
separate into different phases; a lower red phenol-chloroform phase, an interphase and a 
colorless upper aqueous phase, where RNA remains.  The upper aqueous phase was carefully 
withdrawn from each sample without removing any part of the interphase layer and then 
transferred to a new tube.  An equal volume of isopropyl alcohol to the aqueous phase RNA 
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(about 600 ml) was added to precipitate the RNA. Samples were rested at room temperature 
for 10 minutes and centrifuged at 16100 g for 15 minutes at 4°C.   
Supernatants from each tube were discarded while leaving RNA intact at the bottom 
of the tube.  The RNA precipitates were washed in 1 ml of 80% ethanol, vortexed for 10 
seconds and centrifuged at 16100 X g for 15 minutes at 4°C.  The supernatants were again 
decanted leaving RNA precipitates intact.  RNA precipitates were dried by centrifuging 
uncapped tubes for 8 minutes at 300 rpm (4°C).  RNA was dissolved in 30 ml of Rnase-free 
water.  To determine RNA concentration, an absorbance reading at 260 nm was first obtained 
using a spectrophotometer.  The concentration of RNA in each sample was then determined 
using the relationship of an absorbance of 1.0 equaling a concentration of 40 mg/ml of RNA. 
After RNA isolation, all samples were treated for DNA contamination with RQ1 
RNase-free DNase enzyme.  Each sample was incubated at 37°C for 45 minutes with 5 ml of 
RQ1 RNase-free DNase 10X buffer, one unit of RQ1 RNase-free DNase per 1 mg of RNA, 
and enough RNase-free water for a total volume of 50 ml.  After incubation, each sample 
received 1/10 of the sample total volume of DNA inactivator to stop the DNA digestion.  
Samples were rested for 2 minutes at room temperature, and vortexed after the first minute 
was over.  Then, samples were centrifuged at 16100 X g for 2 minutes at room temperature 
and supernatants containing the DNA-free RNA were transferred to new pre- labeled tubes. 
Creation of cDNAs was conducted using1 mg of RNA from each sample.  This 
amount of RNA, along with 1 ml of Random Hexamers (P.E. Applied Biosystems), and 
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enough Rnase-free water to make a total volume of 11.25 ml, was initially heated for 3 
minutes at 70-75°C in a heating block.  After heating, samples were briefly centrifuged to 
collect any condensation and incubated for 5-10 minutes at room temperature to allow RNA 
and hexamers anneal.  Next, each sample received 8.75 ml from a master mix consisting of 8 
ml of 5X M-MLV reaction buffer (Promega), 8 ml of 10 mM dNTP mixture (P.E. Applied 
Biosystems), 1 ml of RNase inhibitor (P.E. Applied Biosystems), and 0.5 ml of M-MLV 
Reverse Transcriptase diluted to 200-units/ml (Promega).  RNA samples were then incubated 
at 42°C in a Lauda water bath for one hour, and then heated at 95°C for 5 minutes to 
inactivate the Reverse Transcriptase.  Samples were briefly centrifuged again to collect any 
condensation and then stored at -80°C. 
Real time RT-PCR was conducted for CCR7 mRNA analysis, using an ABI PRISM 
5700 Sequence Detection System (Applied Biosystems).  PCR reactions were performed 
using 1:5 dilutions from all cDNAs samples, 25 ml of 2X AB gene QPCR master mix, 1.5 ml 
from each 10 mM Forward and Reverse primers aliquots, 1 ml of 100 mM probe aliquot, and 
enough PCR water to make a total volume of 50 ml per reaction.  All reactions were loaded 
into a 96-well PCR plate and assayed in duplicates for 50°C for 2 min cycle, another 95°C 
for 10 min cycle, and 40 cycles of 95°C for 15 sec and 60°C for 1 min.  
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RT-PCR Primers and Probe Sequences 
 CCR7 GAPDH 
F primer 
 
5'-TGGCCTCCGTCCGCT-
3’ 
5' –TGTGTCCGTCG 
TGGATCTGA-3’ 
R Primer 
 
5'-GGTCGCTGCG 
GAACTTGA-3’ 
5'-CCTGCTTCACCA 
CCTTCTTGA-3’ 
Probe 5' -6FAM-TGCGTCAACCC 
TTTCTTGTATGCCTTCAT-
TAMRA-3’ 
5'-6FAM-CCGCCTGGAG 
AAACCTGCCAAGTATG-
TAMRA-3’ 
 
Table 1.  RT-PCR Primers and Probes Sequences. 
Primers used for CCR7 analysis were designed by Primer Express (Applied 
Biosystems) and were specific for a sequence within the mCCR7 gene.  A labeled mCCR7 
probe with a specific sequence from within the CCR7 amplicon was used for all CCR7 
reactions to enhance specificity of the amplicon.  CCR7 PCR values were normalized with 
values from GAPDH PCR reaction.  Sequences for GAPDH primers and probe used for real 
time RT-PCR are listed on Table 1.    
In order to quantify CCR7 mRNA levels, standard curves for CCR7 and GAPDH 
were designed.  Both standard curves were run with a series of dilutions from a known 
cDNA template used as a positive control.  Absorbance values were analyzed by comparing 
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values from the CCR7 and GAPDH PCR reactions for each treatment group’s cDNA to the 
values obtained from both CCR7 and GAPDH standard curves, respectively.  CCR7 mRNA 
expression for each sample was analyzed as a ratio between CCR7 and GAPDH values. 
Statistics 
The purpose of this experiment is to determine differences in the mean of the number 
of migrating cells means between the LA-DC and LM-DC groups.  The design has two 
factors: Condition and Infection.  Condition, which consists of 2 levels, determines whether 
the cells were exposed to the treatment of MIP-3b  or not.  The infection factor consists of 4 
levels specifying whether the cells were infected with L. amazonensis, or L. major, or treated 
with LPS/CD40L, or remained uninfected (control group).  All combinations of factor levels 
were replicated 3 times on 3 different days.  Since day-to-day differences might affect the 
migration behavior of the cells, each day was used as a random block.  Blocks are set of 
homogeneous groups, which constitute a replication of the experiment.  The effect of days is 
not of intrinsic interest, since the purpose of this experiment is not to make inferences 
concerning specific days.  In contrast, condition and infection were considered as fixed 
factors since the interest centers in the differences in the mean of the migrating cells among 
different levels of infection or activation status.  Therefore a Mixed Anova Model was used 
to model the number of migrating cells at each level of the two fixed factors and the random 
block. 
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3. RESULTS 
BM-DC infected with L. major and L. amazonensis promastigotes present 
similar migration responses to MIP-3b  in vitro. 
An in vitro migration assay was used to assess DC migration responses after 
promastigote infection.  BM-DC infected for 24 hours with either L. amazonensis or 
L. major promastigotes, and cells treated with LPS/CD40L as a positive control were 
used for migration assay (see Materials and Methods). 
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Figure 2.    BM-DC migration response to MIP -3b in vitro after infection with L. major and 
L. amazonensis promastigote form.  Migration assay was conducted with BM-DC 
infected for 24 hours with L. amazonensis and L. major promastigotes, or treated with 
LPS/CD40L.  Data of numbers of BM -DC that migrated in response to MIP-3b in 
vitro  is expressed as mean ± standard error. No significant difference was detected 
between LA-DC and LM-DC mean values (P-value: 0.1928).  Results are 
representative of 4 individual experiments.  
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Figure 2 shows migration data expressed as number of cells that migrated in 
response to MIP3b .  As shown on Figure 2, the migration response to MIP-3b was 
equally enhanced for cells infected with L. amazonensis (LA-DC) and L major (LM-
DC) promastigotes.  The migration response recorded for both LA-DC (18,600 ± 
6,300 cells) and LM-DC (17,200 ± 3,900) was 2 fold higher than the response 
displayed by uninfected cells (UN-DC) (7,500 ± 2,600).  Moreover, this migration 
enhancement in LA-DC and LM-DC was similar to the response of LPS/CD40L 
treated cells (positive control).  Clearly the data demonstrates that DC infected with 
L. amazonensis and L. major promastigotes display an enhanced migration response 
to MIP-3b , over uninfected cells. 
Amastigote infected LA-DC exhibit an impaired migration response to 
MIP-3b  in vitro. 
Similar in vitro migration assays were performed on BM-DC infected with 
Leishmania amastigotes.  Fig. 3 shows the mean values of cells that had migrated in 
response to MIP-3b  after 1hr incubation in vitro (see Materials and Methods).  
Interestingly, these migration experiments with amastigotes revealed an inability of 
LA-DC to migrate in response to MIP-3b  in vitro. As Fig. 3 shows, the response to 
MIP-3b by amastigote- infected LA-DC was similar to migration response of UN-DC 
(˜  4,000 cells).  Based on the data collected on these migration experiments, 
amastigotes infected LA-DC (4,800 ± 1,350 cells) display an impaired migration 
response to MIP-3b  in vitro when compared to the migration behavior exhibited by 
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amastigote infected LM-DC (10,830 ± 2090 cells) and the cells treated with 
LPS/CD40L (13,600 ± 2700 cells).   
 
Figure 3.    BM-DC migration responses to MIP-3b in vitro  after infection with amastigote 
form of L. major and L. amazonensis.  Migration assay was conducted with BM-DC 
infected for 24 hours with L. amazonensis and L. major amastigotes, or treated with 
LPS/CD40L.  Data is expressed as mean numbers of cells that migrated in response to 
MIP-3b in vitro  ± standard error.  A significant difference was detected between LA -
DC and LM-DC (P-value: 0.001).  These results are representative of 4 individual 
experiments. 
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IL-12 p40 ELISA 
BM-DC’s ability to produce IL-12 was measured by IL-12 p40 ELISA assays 
performed on supernatants from promastigote and amastigote infected BM-DCs 24 hours 
post-infection (see Materials and Methods).  We also collected supernatants from UN-DC 
and LPS/CD40L-treated BM-DCs for our negative and positive control groups respectively. 
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Figure 4.    Promastigote-infected LA-DC and LM-DC produce similar levels of IL-12 p40.  
Supernatants collected from UN-DC, LA -DC or LM-DC promastigotes after 24 hours 
incubation were used to measure IL-12 p40 production.  Data is expressed as mean 
values ± standard error from a pooled data of 4 individual experiments.  The difference 
between LA-DC and LM-DC IL-12 p40 production was not statistically significant (p-
value: 0.92). A. Standard error value is ± 208 ng/ml. 
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In supernatants from promastigote studies (Fig. 4), both LA-DC and LM-DC 
displayed an enhanced production of IL-12 p40 (˜  30 ng/ml).  The IL-12 p40 production 
from cells infected with the promastigote form of both strains of Leishmania was 
significantly different from levels detected from UN-DC supernatants.  BM-DCs treated with 
LPS/CD40L produced off-charts levels of IL-12 p40 (1803 ± 208 ng/ml). 
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Figure 5.    Production of IL-12 p40 by BM-DC infected with L. amazonensis and L. major 
amastigotes.  IL-12 p40 ELISA was performed on collected supernatants from UN-
DC, LA-DC or LM-DC amastigotes after 24 hours.  IL-12 p40 concentrations are 
expressed as mean values ± standard error from a pooled data of 5 individual 
experiments.  The difference between LA -DC and LM -DC IL-12 p40 production was 
statistically significant (p-value: 0.018).  A. Standard error value is ± 100 ng/ml. 
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The IL-12 p40 ELISA analysis from the amastigote experiments revealed a 
significant difference between LA-DC and LM-DC IL-12 p40 production.  As seen on Fig. 5, 
LA-DC produced half as much IL-12 p40 than LM-DC (12 ng/ml vs. 25 ng/ml).  
Furthermore, the detected IL-12 p40 levels from LA-DC were similar to those recorded for 
UN-DC, suggesting BM-DC infected with L. amazonensis amastigotes do not enhance their 
production of IL-12 p40.  It is interesting to notice that IL-12 p40levels from LM-DC were 
significantly different from UN-DC levels. 
PCR 
DC migration to the lymph node is regulated by the interaction of MIP-3b  with 
CCR7.  To further understand the results obtained from the migration assays, we wanted to 
test if the responses to MIP-3b  in vitro displayed by LA-DC and LM-DC in promastigotes 
and amastigotes experiments correlated with the levels of CCR7 mRNA.  For this purpose, 
we assessed CCR7 expression at the mRNA level using real time RT-PCR technique (See 
Materials and Methods).  Fig. 6 shows real time RT-PCR data expressed as CCR7 and 
GAPDH mRNA ratio from a pooled data of 3 individual promastigotes experiments.  
Although LA-DC and LM-DC display an enhanced migration response to MIP-3b  in vitro in 
migration experiments with promastigotes infected cells, both groups displayed similar 
CCR7 mRNA levels to uninfected BM-DC.  In fact, only LPS/CD40L treated cells displayed 
enhanced CCR7 mRNA levels, which correlate with their enhanced migration response. 
(LPS/CD40L CCR7/GAPDH ratio: 0.56 ± 0.18)   
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Figure 6.    Real time RT-PCR from promastigote experiments CCR7 mRNA production was 
determined through RT-PCR conducted on cDNAs created from total RNA isolated 
from each treatment group. Bars represent mean values ± standard error from 4 
different experiments.   No statistically significant difference was detected. A. 
Standard error value is ± 0.17. 
CCR7 mRNA expression from cells before migration experiments and after 
Leishmania amastigotes infection was also analyzed with real time RT-PCR.   As shown on 
Fig. 7, there was no significant difference of CCR7 mRNA expression between UN-DC, LA-
DC and LM-DC.  In summary, real- time RT-PCR did not detect CCR7 mRNA expression 
differences between UN-DC, LA-DC and LM-DC in both promastigotes and amastigotes 
experiments.  
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Figure 7.    Real time RT-PCR from amastigote experiments. CCR7 mRNA production was 
determined through RT-PCR conducted on cDNAs created from total RNA isolated 
from each treatment group. Bars represent mean values ± standard error from 3 
different experiments.  A. Standard error value is ± 0.23. 
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Intracellular CCR7 staining 
CCR7 expression on BM-DC infected with L. major and L. amazonensis 
promastigotes and amastigotes was also analyzed at the protein level with a commercially 
available CCR7 antibody (CKR7 Ab) by flow cytometry (see Materials and Methods).   
Intracellular CCR7 staining was conducted on 2 experiments with promastigote 
infection (Figs. 8 and 9) and 2 other experiments with amastigote infections (Figs. 10 and 11) 
independent experiments.  Figs. 8-11 each shows 4 histograms representing a treatment 
group (see Materials and Methods) with the isotype control goat IgG staining (purple) and 
CKR7 staining (green).  To test the efficiency and specificity of the CKR7 antibody, we used 
two additional control groups per treatment, one with cells treated with CKR7 Ab diluted in 
FACS buffer without saponin (blue dots) and another with a CKR7 blocking peptide (red).  
(See Materials and Methods) 
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Figure 8. Intracellular CCR7 staining from promastigote experiment treatment groups (A) 
CCR7 flow cytometry analysis for UN-DC, LA-DC, LM-DC, and LPS/CD40L-treated 
cells.  Histograms correspond to fluorescence intensities for IgG isotype (purple), 
CKR7 Ab (green), and CKR7 Ab + CKR7 blocking peptide (red).  (B) MFI readings 
for each control are listed for all treatment groups and were obtained from the 
difference of the geometric mean values (subtracting background fluorescent intensity 
from net fluorescent intensity). 
The MFI values obtained from each treatment are listed on tables at the bottom of 
each figure.  Intracellular CCR7 staining assays conducted on both promastigotes 
experiments failed to provide conclusive results for CCR7 protein expression between 
treatment groups. (Fig. 8 and Fig. 9) The MFI values for both promastigote 
Mean Fluorescent Intensities 
Treatments 
Control Groups  
UN-DC LA-DC LM-DC LPS/CD40L 
CKR7 Ab + 
saponin 
1.75 0.92 1.03 1.26 
CKR7 Ab + 
blocking peptide 
+ saponin 
0.56 0.51 0.25 1.21 
CKR7 Ab - no 
saponin 
0.61 0.52 -0.06 0.42 
A 
B
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experiments detected higher CCR7 expression values on UN-DC than in LPS/CD40L cells 
and LM-DC.  In addition, cells stimulated with LPS/CD40L did not stain positive for CCR7. 
(Fig. 8 and Fig. 9) 
 
 
 
 
 
Figure 9.    Intracellular CCR7 staining from promastigote experiment treatment groups (A) 
CCR7 flow cytometry analysis for UN-DC, LA-DC, LM-DC, and LPS/CD40L-treated 
cells.  Histograms correspond to fluorescence intensities for IgG isotype (purple), 
CKR7 Ab (green), and CKR7 Ab + CKR7 blocking peptide (red), and CKR7 Ab 
without saponin (blue). (B) MFI readings for each control are listed for all treatment 
groups and were obtained from the difference of the geometric mean values 
(subtracting background fluorescent intensity from net fluorescent intensity). 
 
Mean Fluorescent Intensities 
Treatments Control 
Groups  UN-DC LA-DC LM-DC LPS/CD40L 
CKR7 Ab + 
saponin 
1.72 3.85 1.62 -0.01 
CKR7 Ab + 
blocking 
peptide + 
saponin 
1.76 0.57 0.30 0.64 
CKR7Ab - 
saponin 
-0.45 -0.39 0.19 1.13 
A 
B 
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However, intracellular CCR7 staining from amastigotes experiments did show 
different results.  Although LPS/CD40L MFI values were still lower than UN-DC’s, MFI 
values for LM-DC CCR7 staining were reportedly different from LA-DC (Figs. 10 and 11). 
Also, on both amastigotes CCR7 staining analysis LA-DC’s MFI values were similar to UN-
DC’s MFI.  
 
 
 
Figure 10.    Intracellular CCR7 staining from amastigote experiment treatment groups (A) 
CCR7 flow cytometry analysis for UN-DC, LA-DC, LM-DC, and LPS/CD40L-treated 
cells.  Histograms correspond to fluorescence intensities for IgG isotype (purple), 
CKR7 Ab (green).  (B) MFI readings for each control are listed for all treatment 
groups and were obtained from the difference of the geometric mean values 
(subtracting background fluorescent intensity from net fluorescent intensity). 
Mean Fluorescent Intensities 
Treatments Control 
Groups UN-DC LA-DC LM-DC LPS/CD40L 
CKR7 Ab + 
saponin 0.41 0.24 0.98 0.49 
A 
B 
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Figure 11.    Intracellular CCR7 staining from amastigote experiment treatment groups (A) 
CCR7 flow cytometry analysis for UN-DC, LA-DC, LM-DC, and LPS/CD40L-treated 
cells.  Histograms correspond to fluorescence intensities for IgG isotype (purple), 
CKR7 Ab (green), and CKR7 Ab + CKR7 blocking peptide (red).  (B) MFI readings 
for each control are listed for all treatment groups and were obtained from the 
difference of the geometric mean values (subtracting background fluorescent intensity 
from net fluorescent intensity). 
Mean Fluorescent Intensities 
Treatments Control 
Groups UN-DC LA-DC LM-DC LPS/CD40L 
CKR7 Ab + 
saponin 
2.17 1.13 2.94 0.95 
CKR7 Ab + 
blocking peptide 
+ saponin 
1.05 1.37 0.76 1.47 
A 
B 
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4. DISCUSSION 
Previous studies have shown that many factors contribute to host susceptibility after 
L. amazonensis infection.  One factor explores the possibility that L. amazonensis could be 
involved, directly or indirectly, with the inhibition of Ag presentation by DC, therefore 
preventing a proper activation of a Th1 response.  We wanted to test if such limitation of DC 
function could be associated with an inability of LA-DC to migrate towards the draining 
lymph node, therefore reducing the number of mature DC present at the rich T cells areas of 
the lymph node for Ag presentation and proper Th1 activation of CD4+ T cells.  The present 
study was designed to evaluate and compare BM-DC migration responses to MIP-3b  in vitro 
after infection with the promastigote and amastigote forms of L. major and L. amazonensis, 
the two phases of the Leishmania life cycle which interacts with DC during internalization.   
This study demonstrates that after infection with L. major and L. amazonensis 
promastigotes, BM-DC responded to MIP-3b  and enhanced their migration response in vitro.  
In addition, we also examined if BM-DC’s ability to produce IL-12 p40 was also affected 
after infection with both species of Leishmania promastigotes.  Results from IL-12 p40 
ELISA showed that both LA-DC and LM-DC had a similar enhancement in IL-12 p40 
production.  Taken together, these results suggest that not only BM-DC are still able to 
migrate after being infected with either L. major or L. amazonensis promastigotes, but also 
that they are equally activated to enhance IL-12 p40 production. 
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In contrast, BM-DC migration behavior after amastigotes infection was totally 
different from what was observed on the previous promastigote experiments.  The data from 
BM-DC’s migration experiments after infection with L. major and L. amazonensis 
amastigotes revealed that LM-DC have enhanced migration after MIP-3ß activation, whereas 
LA-DC failed to respond to MIP-3b  in vitro.  The migration response displayed by 
amastigote- infected LA-DC was approximately 50 % less than the response from LM-DC on 
theses experiments. (Fig. 3)  In addition, no significant difference was detected between LA-
DC and UN-DC migration responses to MIP-3b  in vitro (Fig. 3). Also, data from IL-p40 
ELISA demonstrated that LA-DC produce half as much IL-12 p40 than LM-DC after 
amastigotes infection (11.7 ± 5.4 ng/ml vs. 25.26 ± 9.36 ng/ml).  Taken together, the data 
from the amastigote experiments indicate that BM-DC infected with L. amazonensis 
amastigotes have an impaired migration and a defective ability to produce IL-12, when 
compared to BM-DC infected with L. major amastigotes.  
It is known that mature DC migration towards the T cell rich areas of the lymph node 
is mediated through the interaction between MIP-3b  and CCR7, the DC’s only known 
receptor for MIP-3b .  Moreover, because DCs are known to up-regulate CCR7 expression 
during maturation, then we expected a concomitant increase of CCR7 mRNA as well.  
Furthermore, RT-PCR could only detect an enhancement in CCR7 mRNA expression from 
LPS/CD40L treated cells.  The enhancement on CCR7 mRNA expression correlated 
perfectly with their enhanced migration response displayed on both promastigotes and 
amastigotes experiments. Yet, a similar enhancement on CCR7 mRNA could not be detected 
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for LA-DC, nor LM-DC from both promastigotes and amastigotes migration experiments.  
Therefore, for a more in depth analysis on CCR7 expression at the protein level, both 
intracellular staining and flow cytometry techniques were used.  However, flow cytometry 
analysis failed to detect an enhancement of CCR7 expression levels on all treatment cells that 
would correlate with the migration data obtained from promastigotes and amastigotes 
experiments, as well as in the PCR mRNA analysis.  This fact may perhaps indicate the 
possibility that CCR7 expression does not necessarily correlate with their migration behavior, 
but rather that CCR7 receptors from LPS/CD40L stimulated cells are more sensitive to MIP-
3ß than those present on UN-DC.  Or it could be that flow cytometry is not the appropriate 
method to analyze CCR7 expression.  
Taken together, these results lead us to many other questions.  There is the possibility 
that the impaired migration response to MIP-3b  in vitro exhibited by amastigote infected LA-
DC could be mediated by blocking of the CCR7 signaling pathway inside the cell.  In 
numerous studies it has been demonstrated how chemokine signaling pathway cascade can be 
interrupted.  There is documented evidence that pertussis toxin inhibits cell migration by 
inhibiting functional coupling of the receptor to the Ga subunit. (35) It has also been 
reported that regulators of G protein signaling (RGS) can accelerate the decay of the active 
GTP bound state of Ga subunit which accelerates the rapid termination of the G protein-
coupled receptor-mediated signal transduction. (61)  In addition, another study addressed the 
role of RGS in the regulation of the chemokine-stimulated chemotaxis and demonstrated that 
the expression of these proteins correlated with inhibition of cell migration. (62)  
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Future studies may evolve around understanding DC’s intracellular CCR7 signaling 
pathway and try to test in which mechanisms or which soluble factors produced by L. 
amazonensis amastigotes can alter CCR7 signaling. 
The different migration patterns observed on all BM-DC treatment groups from 
promastigotes and amastigotes experiments did not correlated with a significant change of 
CCR7 mRNA expression. It could be possible that migration after Leishmania is correlated 
to an increase in CCR7 activity instead of enhanced protein expression, allowing the receptor 
to be more active and more responsive to MIP-3b  signaling.  Unfortunately, our attempt to 
analyze CCR7 protein expression using intracellular staining and flow cytometry failed to 
provide us conclusive data. 
We have demonstrated that amastigotes infected LA-DC exhibits an impaired 
migration response to MIP-3b  in vitro and a defective production of IL-12 p40.  This 
deficiency in migration and IL-12 p40 production are two important events that may lead to 
the failure of mounting an effective Th1 response and the susceptibility of L. amazonensis 
infection.  It is worth mentioning that this event was only observed on amastigotes infected 
LA-DC and not on promastigote infected LA-DC, possibly suggesting that susceptibility is 
closely associated with an event occurring during the parasites amastigote stage. 
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